Cancer Science Institute, National University of Singapore, Singapore, Singapore.
International Research Center for Medical Sciences, Kumamoto University, Kumamoto City, Japan.
Ann N Y Acad Sci. 2020 Apr;1466(1):51-58. doi: 10.1111/nyas.14169. Epub 2019 Jul 10.
Thrombopoietin (Thpo) and its receptor myeloid proliferative leukemia (Mpl) were initially identified as the cytokine signaling that stimulates megakaryopoiesis and platelet production. However, Thpo-Mpl signaling has also been widely characterized as one of the few cytokine systems that directly regulates hematopoietic stem and progenitor cells. The ability of Thpo signaling to stimulate hematopoietic stem cell (HSC) self-renewal has led to the development and utilization of Thpo mimetic drugs to treat hematopoietic diseases with restricted function of HSCs, such as aplastic anemia. This review will cover the mechanisms by which Thpo-Mpl signaling regulates HSCs.
血小板生成素(Thpo)及其受体髓性增殖性白血病(Mpl)最初被鉴定为刺激巨核细胞生成和血小板生成的细胞因子信号。然而,Thpo-Mpl 信号也被广泛描述为少数几个直接调节造血干细胞和祖细胞的细胞因子系统之一。Thpo 信号刺激造血干细胞(HSC)自我更新的能力导致了 Thpo 模拟药物的开发和利用,以治疗 HSCs 功能受限的血液疾病,如再生障碍性贫血。本综述将涵盖 Thpo-Mpl 信号调节 HSCs 的机制。